KROS (Keros Therapeutics) Beginning Cash Position: $288.86 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KROS Keros Therapeutics Inc KROS
30 GF Score
Price $10.64
! 2 Warning Signs
View Full Analysis

What is Keros Therapeutics Beginning Cash Position?

Keros Therapeutics KROS +0.19% 30 Beginning Cash Position is $288.86 Mil as of Mar. 2026. GuruFocus rates KROS with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Keros Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $288.86 Mil.

Keros Therapeutics's quarterly Beginning Cash Position increased from Sep. 2025 ($691.66 Mil) to Dec. 2025 ($694.92 Mil) but then declined from Dec. 2025 ($694.92 Mil) to Mar. 2026 ($288.86 Mil).

Keros Therapeutics's annual Beginning Cash Position increased from Dec. 2023 ($280.38 Mil) to Dec. 2024 ($332.36 Mil) and increased from Dec. 2024 ($332.36 Mil) to Dec. 2025 ($561.38 Mil).

Keros Therapeutics Beginning Cash Position Related Terms

Keros Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Keros Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keros Therapeutics Beginning Cash Position Chart

Keros Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 265.99 231.37 280.38 332.36 561.38

Keros Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 561.38 721.99 691.66 694.92 288.86
KROS
30GF Score
Keros Therapeutics Inc KROS
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Keros Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $288.86 Mil mean?
Keros Therapeutics (KROS) has a Beginning Cash Position of $288.86 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Keros Therapeutics and its competitors.
Is Keros Therapeutics' Beginning Cash Position too high?
Keros Therapeutics' current Beginning Cash Position is $288.86 Mil. Overall, Keros Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Keros Therapeutics' Beginning Cash Position compare to CDXS and CAMP?
Keros Therapeutics' Beginning Cash Position of $288.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Keros Therapeutics and its competitors. Keros Therapeutics's current Beginning Cash Position is $288.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keros Therapeutics stock overvalued right now?
Keros Therapeutics (KROS) has a current Beginning Cash Position of $288.86 Mil. The current Beginning Cash Position is $288.86 Mil. Keros Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current Beginning Cash Position is $288.86 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Keros Therapeutics Business Description

Address 1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
30GF Score

Get the complete analysis for KROS

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.64
Price